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Genome editing often takes the form of either error-prone sequence disruption by non-homologous end
joining (NHEJ) or sequence replacement by homology-directed repair (HDR). Although NHEJ is generally
effective, HDR is often difficult in primary cells. Here, we use a combination of immunophenotyping, next-
generation sequencing, and single-cell RNA sequencing to investigate and reprogram genome editing out-
comes in subpopulations of adult hematopoietic stem and progenitor cells. We find that although quiescent
stem-enriched cells mostly use NHEJ, non-quiescent cells with the same immunophenotype use both NHEJ
and HDR. Inducing quiescence before editing results in a loss of HDR in all cell subtypes. We develop a strat-
egy of controlled cycling and quiescence that yields a 6-fold increase in the HDR/NHEJ ratio in quiescent
stem cells ex vivo and in vivo. Our results highlight the tension between editing and cellular physiology
and suggest strategies to manipulate quiescent cells for research and therapeutic genome editing.
INTRODUCTION
CRISPR-Cas genome editing has emerged as a powerful tool
that enables fundamental research into genotype-phenotype re-
lationships and holds great promise for the treatment of genetic
disease (Doudna and Charpentier, 2014; Fellmann et al., 2017;
Sternberg and Doudna, 2015). Double-stranded DNA damage
induced by CRISPR-Cas enzymes can be repaired by either
error-prone non-homologous end joining (NHEJ) to create indels
and disrupt a locus or templated homology-directed repair
(HDR) to precisely change a sequence. Cell cycle plays an
important role in DNA repair decisions in response to double-
strand breaks (DSBs). In most human cell types, NHEJ is the pri-
mary repair mechanism throughout the cell cycle, whereas HDR
occurs at a much lower rate and primarily happens in S/G2
phase due to template availability and to avoid inappropriate
telomere fusion during mitosis (Branzei and Foiani, 2008; Essers
et al., 2002; Hustedt and Durocher, 2016; Mao et al., 2008;
Orthwein et al., 2014, 2015; Pietras et al., 2011; Saleh-Gohari
and Helleday, 2004). The high levels of NHEJ and correspond-
ingly low levels of HDR in primary cells have complicated both
fundamental research and therapeutic applications that make
use of genome editing.
Primary hematopoietic stem cells (HSCs) ensure the lifelong
production of all blood cells through their unique capacity to
self-renew and to differentiate (Figure 1A). Inadequate HSC
renewal can lead to severe anemia, such as Fanconi anemia
and Diamond-Blackfan anemia (Corey et al., 2007). Inappro-
priate differentiation can lead to either the over- or under-pro-
duction of blood components, causing disorders that range
from immunodeficiency to cancer.
Due to their ability to simultaneously self-renew and generate
the entire blood system, long-term HSCs (LT-HSCs) represent
an attractive target for genome editing to investigate the mech-
anisms of inherited blood disorders and to deliver lasting
treatments. CRISPR-Cas genome editing has emerged as an
effective tool to precisely target human HSCs, but the replace-
ment of genetic sequences by nuclease-induced HDR in HSCs
has lagged behind the ability to disrupt sequences by NHEJ in
these cells (Dever et al., 2016; DeWitt et al., 2016; Genovese
et al., 2014b; Hoban et al., 2015; De Ravin et al., 2017; Wang
et al., 2015). Although bulk-edited CD34+ populations of
hematopoietic stem and progenitor cells (HSPCs) exhibit high
levels of HDR after a few days in culture, it has been highly chal-
lenging to maintain long-term engraftment of HDR-edited HSCs
(Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b;
Hoban et al., 2015; Wang et al., 2015). Without introducing a
selectable marker to isolate HDR events, the prevalence of
HDR alleles in LT-HSCs ranges from less than 1% to 2.5%
(DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al.,
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2015; Wang et al., 2015). The paucity of nuclease-induced HDR
in LT-HSCs could stem from a number of factors, including inef-
ficient delivery of the HDR donor used to program the change,
cell toxicity introduced by the act of performing HDR itself, or
fundamental limitations on HDR imposed by the underlying
biology of LT-HSCs.
HSCs, likemany other adult stemcells, can exist in both cycling
and G0 quiescent states. For HSCs, cycling supports
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Figure 1. HSCs Require More Time to Activate HDR Pathways during Gene Editing Than Differentiated Cells
(A) Diagram describing the human hematopoietic population hierarchy: long-term hematopoietic stem cell (LT-HSC), short-term hematopoietic stem cell (ST-
HSC), multipotent progenitor (MPP), lymphomyeloid-primed progenitor (LMPP), common lymphoid progenitor (CLP), common myeloid progenitor (CMP),
granulocyte monocyte progenitor (GMP), and megakaryocytic-erythroid progenitor (MEP). Immunophenotypic markers for each subpopulation were adapted
from (Corces et al., 2016; Notta et al., 2011).
(B) Fluorescence-activated cell sorting scheme to isolate human progenitors (CD34+ CD38+), engraftment-enriched (EE) HSPCs (CD34+ CD38), MPPs, HSCs,
ST-HSCs, and LT-HSCs from human mobilized peripheral blood (mPB) CD34+ HSPCs. CD34+ cells were stained with monoclonal antibodies against CD34,
CD38, CD45RA, CD90 (Thy1), and CD49f antigens. The frequency of each subpopulation is based on the parent gate.
(C) Editing outcomes in CD34+ subpopulations 1 day post-electroporation and 2 days in culture. Percentage of reads positive for HDR or NHEJ by next-gen-
eration amplicon sequencing at the HBB site. HSCs lack HDR alleles. Representative data from experiments performedwith three different mPB donors and n = 3
biological replicates per donor. Mean ± SD shown. **p < 0.01, ***p < 0.001 by unpaired t test.
(D) Editing outcomes in CD34+ compartments 1 day post-electroporation and 3 days in culture. Percentage of reads positive for HDR or NHEJ by next-generation
amplicon sequencing at the HBB site. HSCs accumulate significant HDR alleles, although they show a lower HDR/NHEJ ratio than that of MPPs and progenitors.
Representative data from experiments performed with three different mPB donors and n = 3 biological replicates per donor. Mean ± SD shown. **p < 0.05 by
unpaired t test.
See also Figure S1.




hematopoiesis, whereas quiescence preserves the stemcell pop-
ulation (Li andClevers, 2010).QuiescentHSCs frommiceprimarily
use NHEJ in response to non-specific DSBs, whereas cycling
mouse HSCs can use both NHEJ and HDR (Beerman et al.,
2014; Mohrin et al., 2010). But human HSCs are distinct from their
mouse counterparts in termsof the frequency of cycling (Abkowitz
et al., 1996;Cheshier et al., 2007;Kiel et al., 2007;Nombela-Arrieta
andManz, 2017), DNA damage response (Biechonski andMilyav-
sky, 2013; Mohrin et al., 2010), and expression of DSB repair
genes (Biechonski and Milyavsky, 2013). The use of cell-cycle-
regulated Cas9 constructs in human HSPCs has enabled de-
creases in deleterious NHEJ alleles, thereby improving HDR/
NHEJ ratios (Lomova et al., 2018). But, explicitly increasing HDR
alleles in quiescent LT-HSCs has proven elusive.
Here, we investigate the relationship between the cell cycle
status of adult human mobilized peripheral blood (mPB)
CD34+ HSPC subpopulations and their editing outcomes. We
find that editing CD34+ HSPCs results in high levels of HDR in
relatively differentiated subpopulations, but G0 HSPCs almost
completely lack HDR alleles. Allowing HSPCs to briefly enter
the cell cycle yields immunophenotypically primitive cells
(CD34+ CD38) with high levels of HDR but few quiescent cells.
We define these CD34+ CD38 immunophenotypically primitive
cells as ‘‘engraftment-enriched’’ (EE) HSPCs for the purpose of
this paper because CD34+ CD38 HSPCs have been shown
to primarily consist of cells that preserve the potential to engraft
(Bhatia et al., 1997; Hao et al., 1995; Hogan et al., 2002; Zonari
et al., 2017). Although CD90, EPCR, or ITGA3 more efficiently
enriches for primitive cells in cultured HSPCs than in CD38 (Mar-
tin and Park, 2017; Tomellini et al., 2019), we used CD38 be-
cauase antibodies for markers other than CD38 that we tested
were not compatible with the fixation step for the simultaneous
cell cycle analysis. Using the timed administration of a small
molecule cocktail originally developed for HSC maintenance,
we developed a protocol to place HDR-edited EE HSPCs back
into quiescence. The end result is G0 EE HSPCs whose HDR
editing efficiency reflects the rest of the CD34+ HSPC popula-
tion. This finding translates to an almost 6-fold increase in
HDR/NHEJ ratios of EE HSPCs. Similar increases in HDR/
NHEJ ratios were found during xenotransplantation in vivo, con-
firming that the re-quiescence protocol leads to higher levels of
HDR in cells with long-term stem cell potential. These data yield
insights into the DNA repair preferences of HSPCs enriched for
engrafting cells and suggest routes to therapeutic protocols for
efficient genome editing to cure blood disorders.
RESULTS
HSCs Require More Time to Activate HDR Pathways
during Gene Editing Than Differentiated Cells Require
Although gene editing reagents have been used to induce
significant levels of HDR editing in bulk CD34+HSPCs, themain-
tenance of HDR for a prolonged period of time after in vivo
engraftment has been challenging (Dever et al., 2016; DeWitt
et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Wang
et al., 2015). In contrast, NHEJ is maintained at high levels during
prolonged engraftment. This could either arise because the act
of editing somehow makes LT-HSCs lose markers of stemness
or because LT-HSCs do not perform HDR. To address this
dichotomy, we first interrogated the extent to which primitive-
ness affects the repair decision after a Cas9-induced DSB in hu-
man mPB CD34+ HSPCs.
WeusedapotentsingleguideRNA (sgRNA)wepreviously found
to efficiently edit human CD34+ HSPCs at the hemoglobin beta
(HBB) locus and an single-stranded oligodeoxynucleotides
(ssODN) donor template designed to modify the causative HBB
mutation involved in sickle cell disease (SCD) (Figure S1A;Cradick
et al., 2013; DeWitt et al., 2016). After editing bulk CD34+ HSPCs,
we measured the efficiency of HDR and NHEJ in immunopheno-
typically sorted HSCs (CD34+ CD38 CD45RA CD90+), multi-
potent progenitors (MPPs; CD34+ CD38 CD45RA CD90),
and progenitors (CD34+ CD38+) (Figures 1A and 1B). Editing effi-
ciency was quantified by using next-generation amplicon
sequencing encompassing the HBB target site (Figure S1B).
We cultured CD34+ HSPCs in stem cell expansion media con-
sisting of SFEMII and CC110 cytokine cocktail (SC) for 1 day,
electroporated the cells with HBB-targeting Cas9 ribonucleo-
protein complexes (RNPs), and cultured the HSPCs for 1 day
before separating several HSPC subsets by using fluores-
cence-activated cell sorting (FACS) and assessing the editing
efficiency in each subset through next-generation sequencing
(NGS) genotyping (Figure 1C, top). Both HDR and NHEJ were
evident in bulk CD34+ cells and relatively differentiated progen-
itors (CD34+ CD38+). Total editing was somewhat reduced in
MPPs (CD34+ CD38 CD45RA CD90). Strikingly, we found
moderate amounts of NHEJ in immunophenotypic HSCs
(CD34+ CD38 CD45RA CD90+) but almost no HDR in these
cells, which led to a 3-fold lower HDR/NHEJ ratio in HSCs than
to bulk CD34+ HSPCs. (Figure 1C).
We further cultured the sorted populations (HSCs, MPPs, and
progenitors) and found that HSCs eventually accumulated HDR
edits but only 72 h after electroporation (Figure S1C). However,
the HDR/NHEJ ratio was highest in progenitors and lowest in
HSCs even 72 h after electroporation (Figure S1C). In contrast,
keeping CD34+ HSPCs in culture for 2 days before electropora-
tion led to the appearance of significant HDR edits just 1 day
after electroporation (Figure 1D). HDR was evident in all HSPC
subtypes, including HSCs. These data indicate that more primi-
tive HSCs preferentially repair Cas9-induced DSBs by NHEJ, but
additional time in culture before the introduction of a DSB acti-
vates pathways related to HDR.
Establishing the Timing of Cell Cycle Status in CD34+
Subsets during Ex Vivo Culture
HSPC primitiveness is linked to slower entry into the cell cycle
(Laurenti et al., 2015) as well as lower frequency of cell cycle
(Bradford et al., 1997; Morrison and Weissman, 1994; Pietrzyk
et al., 1985; Suda et al., 1983; Uchida et al., 2003), and cell cycle
progression is a major hallmark of increasing time in culture for
HSPCs. Because HDR is intimately linked with cell cycle, we
hypothesized that HSCs cannot use HDR at short culture time
points due to quiescence resulting from slow entry into the cell
cycle.
Although the cycling properties of freshly isolated mouse and
human HSC subpopulations have been described (Benveniste
et al., 2010; Cheshier et al., 1999; Copley et al., 2012; Foudi




et al., 2009; Laurenti et al., 2015; Oguro et al., 2013; Passegué
et al., 2005; Qiu et al., 2014;Wilson et al., 2008), the cycling prop-
erties of human CD34+ HSPCs during extended ex vivo culture
are not fully established. Before investigating the relationship be-
tween cell cycle status and editing efficiency, we first explored
the cell cycle progression of CD34+ cells in ex vivo culture by us-
ing immunophenotyping combined with Hoechst 33342 (stains
for DNA) and Ki67 (highly expressed in proliferating cells) stain-
ing. (Gerdes et al., 1984; Kim and Sederstrom, 2015). We found
that more than 50% of cryopreserved mPB CD34+ HSPCs are
quiescent (in G0) when thawed, but they gradually enter the
cell cycle and are fully cycling by 3 days in SC culture (Figures
2A, 2B, and S2).
We next examined CD34+CD38HSPCs, which contain most
of the engraftment potential within the CD34+ population and are
enriched for primitive populations, such as HSCs and MPPs, as
well as the more differentiated progenitor CD34+ CD38+ popula-
tions. For simplicity, here, we define CD34+CD38HSPCs as EE
HSPCs. Interestingly, EE HSPCs have a delayed exit from quies-
cence compared to progenitors (Figures 2A, 2C, 2D, and S2).
When cells are edited after only 1 day in culture (Figure 1C),
80% of EE HSPCs are quiescent at the time of editing, whereas
70% of CD34+ CD38+ progenitors are cycling (Figures 2C, 2D,
and S2). These results support the absence of HDR in quiescent
cells and correlate with the vast difference in HDR efficiency be-
tween HSCs and progenitors (Figure 1C). In contrast, when cells
are edited after 2 days in culture (Figure 1D), more than 50% of
the EEHSPCs have begun to actively cycle. This finding could ac-
count for the significant amount of HDR observed in HSCs during
longer ex vivo culture (Figures 1D, 2C, and 2D).
Quiescent CD34+ HSPCs Perform Only NHEJ, but
Cycling CD34+ HSPCs Perform both NHEJ and HDR
To directly test how cell cycle status affects editing of human
adult stem cells, we edited CD34+ HSPCs after 1 day in culture,
allowed them to resolve edits for another day in culture, sorted
them by cell cycle status, and used amplicon NGS to assess
each population’s editing outcomes (Figures 3A, top,
and S3A). One day after editing, we found that cells in G1 and
S-G2-M stages had a substantial amount of HDR alleles, but
quiescent G0 CD34+ HSPCs almost completely lacked HDR al-
leles and had a 3-fold decrease in the HDR/NHEJ ratio
compared to cycling HSPCs (Figure 3A). We observed NHEJ al-
leles in significant amounts regardless of cell cycle, although the
highest amount was observed in the S-G2-M population (Fig-
ure 3A). Intriguingly, 6 h after editing, we found small amounts
of NHEJ alleles across various cell cycle subpopulations, but
HDR alleles do not appear in any of the cell cycle subpopula-
tions, which is consistent with reports from other cell types
that found HDR takes longer than NHEJ (Arnoult et al., 2017;
Mao et al., 2008; Figure S3B).
We next asked whether additional time in culture altered
CD34+ HSPC editing outcomes according to cell cycle status.
Because Hoechst staining led to a significant decrease in
viability in CD34+ HSPCs (Figures S3C and S3D), we developed
a live cell staining protocol that uses Pyronin Y that can stain
both DNA and RNA when used alone (Darzynkiewicz et al.,
1987, 2004). Cells were cultured for 2 days and then edited
and immediately subjected to a live cell cycle sort using
Pyronin Y accumulation (Figures 3B, top, and S3E). Sorted sub-
populations were cultured for an additional 2 days before NGS
genotyping to allow edits to resolve according to cell cycle status
(Figure 3B, top). Similar to short-culture experiments, we
observed NHEJ in cells regardless of cell cycle (Figure 3B, mid-
dle). Unlike short-culture experiments, quiescent G0 cells kept in
culture for a total of 4 days displayed substantial HDR alleles
(Figure 3B, left).
Because almost all CD34+ cells exit quiescence within 3 days
in culture (Figure 2), CD34+ HSPCs that are still in G0 at the time
of editing (mostly CD34+ CD38 EE HSPCs) should exit
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Figure 2. Cell Cycle Progression of Human
mPB CD34+ Cells in Ex Vivo Culture
(A) Representative flow cytometry plots for as-
sessing cell cycle status in CD34+, CD34+ CD38+
(progenitors), and CD34+ CD38 (EE) populations.
CD34+ cells were stained with antibodies against
Ki67 and Hoechst 33342. G0: 2N DNA and Ki67
negative, G1: 2N DNA and Ki67 positive, S/G2/M:
4N DNA and Ki67 positive.
(B) Cell cycle status of CD34+ cells in ex vivo culture.
Notably,60% of bulk CD34+ cells are in G0 at day
0, and 100% of the cells are cycling by day 3.
(C) Cell cycle status of CD34+38+ progenitor cells in
ex vivo culture. More than 50% of progenitor cells
are cycling at day 0, and the percentage of cycling
cells continually increase until day 3.
(D) Cell cycle status of CD34+38 EE HSPCs in
ex vivo culture. Notably,90% of the EE HSPCs are
quiescent at day 0, and EE HSPCs gradually exit
quiescence until day 3 where 100% of them are
cycling.
Representative data from experiments performed
with three different mPB donors and n = 2 biological
replicates per donor.
See also Figure S2.




quiescence by the end of a long-term culture and would be able
to accumulate significant HDR alleles while cycling. Hence, our
results overall suggest that non-cycling CD34+ HSPCs in G0
are highly enriched in primitive EE HSPCs and heavily rely on
the NHEJ pathway, as opposed to HDR. In contrast, cycling cells
in G1 and S-G2-M are enriched in more differentiated CD34+
CD38+ progenitors and use both HDR and NHEJ.
Preventing Exit from Quiescence Blocks HDR Repair in
CD34+ HSPCs
Our previous experiments showed that quiescent, primitive
HSPC subsets are less likely to perform HDR than cycling,
differentiated subsets. We next tested whether induction of
quiescence was sufficient to affect HDR levels under other-
wise HDR-competent conditions, thereby directly testing
whether quiescence was the causative factor of reduced
HDR in HSCs.
We induced quiescence by using either retinoic acid,
which has been shown to drive mouse HSCs into deep
dormancy (Cabezas-Wallscheid et al., 2017), or inhibitors of
mammalian target of rapamycin (mTOR) (rapamycin) and GSK-
3 (CHIR9901), which have been used to maintain mouse and hu-
man HSCs ex vivo and in vivo (Huang et al., 2012; Figure S3F).
We found that treatment of CD34+ HSPCs with retinoic acid in
SC media led to differentiation, as measured by the substantial
loss of CD34 expression, which could potentially be due to the
differences in the maintenance of HSCs in mouse and human,
whereas a combination of rapamycin and CHIR99021 in X-
VIVO media (XRC) led to the prevention of cell cycle entry while
maintaining primitiveness (Figures S3F–S3H).
We investigated editing outcomes in CD34+ HSPCs cultured
in XRC as compared to SC expansion media. We used three
different treatment regimens (Figure 3C). One set of HSPCs
was kept in SC both before and after editing. A second set
was started in XRC before editing and then either maintained
in XRC after editing or moved to SC after editing. All cells
were sorted based on cell cycle, and editing outcomes for
each stage of the cell cycle weremeasured by NGS. Cells main-
tained in SC media entered cell cycle as normal, exhibiting a
decrease in G0 cells and increase in G1 and S-G2-M cells after
3 days. Pre-treatment of CD34+ HSPCswith XRC led to the pre-
vention of cell cycle entry, with almost all cells in G0 after 3 days
(Figure 3D). Treatment with XRC was not associated with a
decrease in cell viability (Figure 3E), and moving XRC-treated
cells to SC media allowed HSPCs to re-enter the cell cycle, as
measured by a decrease in G0 cells and increase in G1 and
S-G2-M (Figure 3D).
Strikingly, quiescent CD34+ HSPCs treated continuously with
XRC repaired almost all Cas9-induced DSBs by using NHEJ and
harbored almost undetectable levels of HDR alleles (Figure 3F).
Moving XRC-treated HSPCs to SC media after editing led to
increased levels of HDR, but this result was mostly confined to
cells in G1 and S-G2-M. HSPCs maintained in SC before and af-
ter editing exhibited low levels of HDR in G0 cells, but high levels
of HDR in G1 and S-G2-M (Figure 3F). These results show that
small-molecule-induced quiescence in HSPCs is sufficient to
prevent HDR even after multiple days in ex vivo culture and
that cycling is necessary for high levels of HDR.
Inducing Quiescence after a Short Period of Cycling
Yields Quiescent, Primitive HSPCs That Harbor HDR
Alleles
Although XRC treatment has previously been used to maintain
stemness (Huang et al., 2012), we next asked whether these
compounds could induce quiescence after HSPCs have been al-
lowed to cycle. Our overall goal was to allow HSPCs to cycle to
accumulate HDR alleles during editing and then to place them
back into G0 to maintain stemness.
We edited CD34+ HSPCs and cultured them in SC media to
allow them toenter the cell cycle (Figure 4A). On the day of electro-
poration,50%ofCD34+HSPCswerequiescent, asexpected (Fig-
ure S4A). Two days after editing, we sorted cells based on cell cy-
cle and quantified editing outcomes byNGS.We found that at this
timepointmostcells hadexitedG0andwere inG1orS-G2-M (Fig-
ure 4B), although less of EE HSPCs were in S-G2-M than the pro-
genitors (Figure S4B). As before, HDR alleles were almost
completely absent from the remaining G0 cells but present in G1
andS-G2-Mcells,whereasNHEJalleleswerepresent in all stages
of the cell cycle (Figure 4C). HDR/NHEJ ratio was 7 times lower in
G0 cells than G1 and S-G2-M cells. We then kept the remaining
HSPCs in SC to allow cycling to continue for another 3 days or
moved them to XRC to induce quiescence. Six days after editing
(3 days in SCand 3 additional days in either SCor XRC), we sorted
based on cell cycle and quantified repair outcomes by NGS.
HSPCs that weremaintained continuously in SCmedia (SC SC
HSPCs) were almost completely lacking in G0 cells by 6 days af-
ter editing (Figure 4D). The remaining cells, whichwere only in G1
or S-G2-M, harbored high levels of HDR alleles (Figure 4E). In
contrast, cells moved to XRC (SC XRC HSPCs) had almost
40% G0 cells and relatively few cells in S-G2-M (Figure 4D). As
XRC treatment induces quiescence and SC promotes expansion
and differentiation, SC XRC cultures overall yielded 50% less
cells than SC SC cultures (Figure S4C). Notably, 60% of the
primitive EE HSPCs returned to quiescence compared to 30%
of CD34+38+ progenitors (Figure S4D). We found that the G0
cells in XRC now harbored high levels of HDR alleles and were
in fact comparable in HDR to G1 and S-G2-M cells (Figure 4E).
We show that XRC treatment maintains stemness (Figure S4E)
and supports viability (Figure S4F) and is distinctive from the
omission of cytokines that generally leads to a loss of CD34+
expression and viability (Figures S4E and S4F). We further found
that post-treatment with XRC led to enrichment in EE HSPCs
compared to continued culture in SC (Figure 4F). However,
because using CD34+ CD38 to enrich for engrafting stem cells
has its limitations especially under prolonged culture, we further
tested the effects of XRC through single-cell RNA sequencing
(scRNA-seq) and in vivo xenotransplantation.
To thoroughly characterize the effects of re-quiescence on
HSPC sub-populations, we carried out scRNA-seq on HSPCs
maintained continuously in SC after Cas9 editing (SC SCHSPCs)
or moved to XRC briefly after Cas9 editing (SC XRC HSPCs). We
also performed scRNA-seq on cells that have only been in SC
culture for 1 day, as a control for primitive cells with minimum
exposure to ex vivo culture. To maximize the resolution of each
primitive population, we enriched relatively rare HSCs by sorting
CD34+ CD38low HSPCs from CD34+ HSPCs that had been
treated with either SC or XRC for 3 days (Figure 5A).








Figure 3. Quiescent CD34+ HSPCs Perform Only NHEJ, but Cycling CD34+ HSPCs Perform Both NHEJ and HDR
(A) Editing outcomes in CD34+ subpopulations in different cell cycle status. One day post-electroporation and 2 days in culture. Percentage of reads positive for
HDR or NHEJ by next-generation amplicon sequencing at the HBB site. G0 CD34+ HSPCs in 2-day culture do not accumulate HDR alleles. Representative data
from experiments performed with three different mPB donors and n = 3 biological replicates per donor. Mean ± SD shown. **p < 0.01 by unpaired t test.
(B) Editing outcomes in CD34+ subpopulations sorted into different cell cycle statuses. Two days post-electroporation and 4 days in culture. Percentage of reads
positive for HDR or NHEJ by next-generation amplicon sequencing at the HBB site. G0 CD34+ HSPCs sorted at 2 days in culture accumulate significant HDR
alleles in 4-day culture. Representative data from experiments performed with three different mPB donors and n = 3 biological replicates per donor. Mean ± SD
shown. *p < 0.05 by unpaired t test.
(C) Schematic of the workflow for mTOR and GSK-3 inhibition with rapamycin and CHIR99021 (XRC) for inhibition of cell cycle entry. Culture condition are
SFEMII + CC110 (SC) and X-VIVO15 + rapamycin + CHIR99021 (XRC).
(D) Cell cycle profiles of CD34+ cells in SC or XRC at the time of electroporation (day 1) and two days post-nucleofection (day 3). XRC prevents cell cycle entry, but
this can be reversed by placing the CD34+ cells in SC media. Representative data from experiments performed with three different mPB donors and n = 2
biological replicates per donor. Mean ± SD shown.
(E) Percentage of early and late apoptosis was assessed by staining the cells for annexin V (AnnV) and propidium iodide (PI) at 2 days post-nucleofection.
AnnVPI, viable; AnnV+PI, early apoptotic; AnnV+PI+, apoptotic. XRC does not induce apoptosis. Representative data from experiments performed with
three different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown.
(F) Editing outcomes in CD34+ cells kept in SC media or XRC in different cell cycle status 2 days post-nucleofection and 3 days in culture. Inhibition of cell cycle
entry by XRCblocks HDR repair but is reversible. Representative data from experiments performedwith three different mPBdonors and n = 2 biological replicates
per donor. Mean ± SD shown.
See also Figure S3.




To identify conserved subpopulations of CD34+ CD38low
HSPCs in control datasets, we performed integrated analysis
of day 1 and SC SC datasets by using the Seurat v3.1.4 package
(Butler et al., 2018; Stuart et al., 2019). Alignment and integrated
clustering of the day 1 and SC SC datasets revealed seven
distinct clusters, which we assigned to HSPC subpopulations
by comparison of cluster marker genes to transcriptional signa-
tures of defined cell types in previously published bulk and
scRNA-seq datasets (e.g., HLF and AVP for HSC/MPPs, CTSG
and IGLL1 for lymphomyeloid-primed progenitors (LMPPs),
DNTT and JCHAIN for common lymphoid progenitors (CLPs),
CNRIP1 and FCER1A for common myeloid progenitors
(CMPs), F13A1, PF4 for granulocyte monocyte progenitors




Figure 4. Inducing Quiescence after a Short Period of Cycling Yields Quiescent, Primitive HSPCs That Harbor HDR Alleles
(A) Schematic of theworkflow for inducing quiescence after a short period of cycling. CD34+ HSPCs are placed in SC culture for 1 day before editing and cycle for
2 additional days in SC culture, and then quiescence is induced with XRC for 3 days before the cells are subjected to FACS based on their cell cycle status and
genotyped by NGS.
(B) Cell cycle profiles of CD34+ cells 3 days in culture (SC). Most CD34+ HSPCs are cycling at day 3. Representative data from experiments performed with three
different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown.
(C) Editing outcomes in CD34+ cells 3 days in culture (SC). HDR repair does not take place in G0 CD34+ HSPCs. Representative data from experiments per-
formed with three different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown. **p < 0.01 by unpaired t test.
(D) Cell cycle profiles of CD34+ cells 6 days in culture (3 days in SC media and 3 additional days in SC media or XRC). Three days in XRC induces quiescence in
30% of the cells. Representative data from experiments performed with three different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown.
**p < 0.01 by unpaired t test.
(E) Editing outcomes in CD34+ cells 6 days in culture (3 days in SCmedia and 3 additional days in SCmedia or XRC). Three days in XRC results in HDR edits in G0
CD34+ HSPCs. Representative data from experiments performed with three different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown.
(F) Percentage of CD34+ cells that are CD34+CD38+ (progenitors) versus CD34+CD38 (EE HSPCs) 6 days in culture. CD34+ cells that regained quiescence in
XRC include a higher proportion of EE HSPCs than CD34+ cells maintained solely in SC media. Representative data from experiments performed with three
different mPB donors and n = 2 biological replicates per donor. Mean ± SD shown. **p < 0.01 by unpaired t test.
See also Figure S4.









Figure 5. Single-Cell RNA Sequencing Indicates That XRC Treatment Leads to the Maintenance of Quiescent HSC/MPPs
(A) Schematic of the workflow for single-cell RNA sequencing (scRNA-seq). CD34+ HSPCs are placed in SC culture for 1 day before editing and cycle for 2
additional days in SC culture, and then quiescence is inducedwith XRC for 3 days before the cells are subjected to FACS of CD34+CD38low cells and sequenced.
(B) UMAPs of scRNA-seq using Seurat 3,s integrated analysis for day 1+SC SC and anchor transfer to SC XRC. Number of cells in day 1 = 2,454, SCSC= 5,686,
and SC XRC = 3,595.
(C) Fraction of cell assignments for each dataset.
(legend continued on next page)




progenitors [MEPs]) (Figures S5 and S6; Table S1; Buenrostro
et al., 2018; Corces et al., 2016; Velten et al., 2017). We identified
one cluster each as HSC/MPPs, LMPPs, CLPs, and CMPs and
two clusters each as GMPs and MEPs in the day 1/SC SC inte-
grated dataset (Figures 5B, S5, and S6). As expected, extended
treatment in SC SC led to differentiation and loss of primitive
HSPCs. Specifically, 86.5% of the CD34+ CD38low HSPCs
sequenced 1 day after thaw clustered as HSC/MPPs, whereas
only 8.1% of SC SC CD34+ CD38low cells cluster as HSC/
MPPs (Figures 5B, 5C, S6B, and S6C).
Having identified cell types from the control scRNA-seq data-
sets, we transferred these labels and clusters to the experi-
mental SC XRC condition and compared the abundances of
each cell population (Stuart et al., 2019). Strikingly, SC-XRC-
treated CD34+ CD38low cells contained 80.8% of cells with an
HSC/MPP transcriptional signature, which is approximately 10
times higher than that of SC SC (Figures 5B and 5C). SC SC
34+38low cells were highly enriched in GMPs, MEPs, LMPPs,
and CMPs, whereas SC XRC 34+38low cells were highly
enriched in more primitive HSC/MPPs. (Figures 5B and 5C).
Transcripts important for HSC regenerative potential were upre-
gulated in the HSC subset under both the day 1 and SC XRC
conditions (Figures S5 and S6D), including HLF and PROM1
(CD133) (Hess et al., 2006; Komorowska et al., 2017). Although
day 1/SC SC and SC XRC conditions followed a similar trend
for the expression of marker genes, they were not completely
identical because (1) many genes are expressed at much lower
level in the SC XRC dataset due to induction of quiescence by
XRC and (2) most cells in the SC XRC condition are assigned
to the HSC/MPP cluster, leaving limited numbers of cells in other
clusters in the SC XRC condition (Figure S5). Overall, these data
indicate that re-quiescence with SC XRC helps maintain an HSC
program.
We analyzed the single-cell expression of cell cycle markers to
determine whether the XRC re-quiescence strategy increased
the proportion of non-cycling cells. Each cell was scored for
cell cycle status based on its expression of 43 G1/S markers
and 55 G2/M markers (Butler et al., 2018; Kowalczyk et al.,
2015; Tirosh et al., 2016; Figures 5D, 5E, and S6E). Most day 1
cells were classified as G0 because they lacked both G1/S
markers (e.g., TYMS, PCNA, MCM2, and CDCA7) and G2/M
markers (e.g., CDK1, CKS1B, CCNB2, and CDC20). SC SC cells
were clearly progressing through the cell cycle, as they
expressed very high amounts of G1/S and G2/M markers. In
contrast, SC XRC cells were more similar to day 1 cells and
mostly scored as G0 (Figure 5D). This includes cells identified
as HSC/MPP by single-cell global transcriptome analysis
(Figure 5B).
We further analyzed the single-cell transcriptomic data to es-
timate the differentiation progress of individual HSPCs using
pseudotime analysis (Cao et al., 2019; Trapnell et al., 2014).
Tracking transcriptome changes as a function of progress along
the learned differentiation trajectory, we found that SC SC treat-
ment yields increasingly heterogeneous subpopulations that are
mostly advanced in pseudotime and differentiation. In contrast,
day 1 and SC-XRC-treated cells mostly consist of primitive pop-
ulations with a small proportion of differentiated cells (Figure 5F).
Overall, our scRNA-seq data reveal that continued culture in SC
after Cas9 editing drives cycling and differentiation, whereas
moving edited cells to XRC after a brief period of cycling induces
quiescence and increases the proportion of transcriptionally
defined HSC/MPPs.
To evaluate the effect of XRC treatment on editing in long-term
engrafting HSCs, we transplanted edited SC SC HSPCs and SC
XRC HSPCs into immunodeficient non-obese diabetic (NOD)
severe combined immunodeficiency (SCID) Il2rg/ (NSG)
mice (Figure 6A). We also xenotransplanted HSPCs that had
been cultured in SC for only 3 days as a negative control for
the effects of extended culture. Engraftment was measured by
the percentage of human CD45 versus mouse CD45.1
(Figure 6B).
We found no significant differences in engraftment of human
cells in mice transplanted with CD34+ cells from different culture
conditions (bone marrow, SC: 10.425% ± 10.54, SC SC: 2.90%
± 2.27, SC XRC: 3.59% ± 2.59; spleen, SC: 3.23% ± 3.08, SC
SC: 1.42% ± 2.08, SC XRC: 1.47% ± 1.44; peripheral blood,
SC: 0.81% ± 0.64, SC SC: 0.30% ± 0.27, SC XRC: 0.61% ±
0.49) (Figure 6C). Furthermore, culture condition did not affect
the potential for ex vivo multilineage differentiation (Figures 6B,
6D, and 6E). Notably, in SC-XRC-treated cells, we found that
high levels of HDR alleles persisted after long-term in vivo
engraftment. Most HDR alleles were instead lost under the SC
and SC SC conditions (Figures 6F and 6G). SC XRC HDR was
5- to 6-fold higher than either the SC or SC SC conditions, and
we found levels of HDR in SC-XRC-treated long-term engrafting
human cells as high as 28% (Figure 6G). NHEJ alleles were pro-
portionately reduced after SC XRC treatment, suggesting a
tradeoff between HDR and NHEJ within equivalent total editing.
The HDR/NHEJ ratio after SC XRC treatment was approximately
0.25 (Figure 6G). Together with our ex vivo data, these findings
indicate that XRC enriches for HDR in repopulating stem cells
by encouraging HDR-edited cells to re-enter G0 (Figure 6G). In
summary, we have developed a strategy to enable high-effi-
ciency HDR in primitive and quiescent HSPCs. This strategy al-
lows HSPCs to briefly cycle after Cas9-mediated induction of a
DSB to allowHDR and then places cells back into quiescence af-
ter HDR alleles have been acquired.
DISCUSSION
Our data provide an approach to ‘‘scarlessly’’ (without selectable
markers) introduce mutations to human HSCs for fundamental
research, to suggest ways to treat gene-edited HSCs for thera-
peutic purposes, and to also shed light on fundamental HSC
biology. The DNA repair decisions after a DSB in primitive human
hematopoietic cells are essential for cell survival; yet, they are
(D) Cell cycle status of single cells based on G1/S and G2/M scores.
(E) Cell cycle status predicted through gene expression.
(F) Pseudotime estimates with HSC/MPPs as the root showing the inferred differentiation of day 1/SC SC and SC XRC datasets.
See also Figures S5 and 56 and Table S1.








Figure 6. Xenotransplantation Indicates That XRC Treatment after Gene Editing Leads to Efficient HDR in Long-Term Engrafting HSCs
(A) Schematic of the workflow for xenotransplantation. CD34+ HSPCs are placed in SC culture for 1 day before editing and cycle for 2 additional days in SC
culture, and then quiescence is induced with XRC for 3 days before xenotransplantation into NSGmice. Sixteen weeks post-transplant, bonemarrow is collected
for engraftment analysis, multilineage analysis, and NGS genotyping; spleen is collected for engraftment analysis; and peripheral blood is collected for
engraftment and multilineage analysis.
(B) Gating strategy for measuring human cell engraftment and multilineage differentiation.
(legend continued on next page)




underexplored due to difficulties in studying human HSCs. Aged
human hematopoietic cells show elevated levels of unresolved
DSBs and increased mutation frequencies, but the mechanisms
underlying DSB repair in these cell types are largely unknown
(Beerman et al., 2014; Genovese et al., 2014a; Rossi et al.,
2007; R€ube et al., 2011; Cancer Genome Atlas Research
Network et al., 2013). Here, we have used CRISPR genome edit-
ing to induce a precise DSB in mixed CD34+ HSPCs and
measured its repair in various cell subtypes and phases of the
cell cycle by a combination of FACS and NGS of sorted popula-
tions. This general experimental strategy could broadly accel-
erate in-depth probing of DNA repair decisions in many different
cell types with available immunophenotypic markers.
We found that genome editing of CD34+ HSPCs leads to high
levels of NHEJ in multiple cell subtypes but that HDR is preferen-
tially missing from more primitive quiescent cells. Instead, HDR
accumulates in relatively differentiated cells and immunopheno-
typically primitive cells that have exited quiescence. Several
groups have reported that genome editing CD34+ HSPCs leads
to high-efficiency HDR in relatively short-term in vitro culture that
drops dramatically during long-term in vivo engraftment (Dever
et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban
et al., 2015; Wang et al., 2015; Wu et al., 2019). This is true
even with very different modalities of Cas9 (mRNA, recombinant
protein), guide RNA (synthetic, adeno-associated virus (AAV) ex-
pressed), and HDR donor (single-stranded DNA, AAV6) (Dever
et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban
et al., 2015; Kim et al., 2014; Wang et al., 2015). A recent report
also found that a specific subtype of base editing by nucleotide
deaminases at the BCL11A erythroid enhancer is less efficient in
quiescent human HSCs than in non-quiescent progenitor cells
(Zeng et al., 2020). Our results indicate that the observed in vivo
lack of HDR is not caused by an inability to target immunopheno-
typic LT-HSCs, nor toxicity caused by the act of performing HDR
itself (Ihry et al., 2018), but is instead because the repopulating
HSCs are in an inappropriate phase of the cell cycle to perform
HDR. Forcing cycling HSCs into quiescence immediately after
editing is sufficient to completely abrogate HDR alleles, and al-
lowing HSCs to cycle briefly and then inducing quiescence en-
ables HDR.
Mechanistic investigations of DNA repair have established
that HDR is preferentially active in the S/G2 stages of the cell
cycle, probably to avoid deleterious telomere fusions that can
occur if HDR is active during mitosis (Orthwein et al., 2014).
Non-mitotic cells such as HSCs, therefore, represent a chal-
lenge. For HSCs, division is central to self-renewal and differen-
tiation, but stemness is intricately linked to long-term quiescence
(Ema et al., 2000; Morrison and Weissman, 1994; Suda et al.,
1983). Prolonged in vitro culture of HSCs leads to a loss of stem-
ness, entry into the cell cycle, and poor engraftment (Morrison
and Kimble, 2006; Wilson et al., 2008). Therefore, there is a ten-
sion between HDR editing and the maintenance of stemness by
quiescence. LT-HSCsmay need to lose a defining feature of their
stemness to obtain HDR edits.
One might avoid HDR entirely and instead pursue NHEJ-
based editing. In HSCs, this approach shows promise for the
treatment of SCD, in which disruption of various repressor
elements leads to re-expression of protective fetal hemoglobin
(Bauer et al., 2013; Bjurström et al., 2016; Canver et al., 2015;
Chang et al., 2017). NHEJ is well-represented in long-term en-
grafting HSCs during genome editing (Dever et al., 2016; DeWitt
et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Wang
et al., 2015; Wu et al., 2019), and here, we show by immunophe-
notyping and cell cycle analysis that HSCs in G0 are fully capable
of accumulating NHEJ alleles. However, limiting oneself to
NHEJ-based editing does not fully tap the potential of genome
editing. Many fundamental questions are best answered by sur-
gically replacing genomic sequences, and relatively few genetic
diseases can be cured by NHEJ-based sequence disruption.
Our lab and others have found that the drop in levels of HDR af-
ter long-term CD34+ engraftment is reflected in low HDR but high
NHEJ in the quiescent LT-HSC subpopulation. In contrast, cycling
progenitor cells and even MPPs exhibit significant levels of HDR.
Previous efforts to increase the HDR/NHEJ ratio in LT-HSCs
focused on use of a Cas9-geminin fusion mRNA to reduce
nuclease activity in G1, where NHEJ is prevalent but HDR is
low. This procedure reduces deleterious NHEJ alleles but
does not increase absolute levels of HDR (Lomova et al., 2018).
We pursued a complementary approach, reasoning that rapid
RNP-based editing followed by progression through at least one
cell cycle and subsequent re-quiescence should increaseHDR al-
leles in HSCs (Branzei and Foiani, 2008; Hustedt and Durocher,
2016). SC XRC treatment indeed resulted in quiescent LT-HSCs
that exhibit 5- to 6-fold increases in HDR up to almost 30% of al-
leles, which is close to those observed in cycling progenitors. Our
data show that treatment with rapamycin and CHIR99021 triggers
pathways that affect cell cycle control and lead to a change in
preference between NHEJ and HDR. In principle, the SC XRC
strategy could be combined with Cas9-geminin to simultaneously
reduce NHEJ and increase HDR in HSCs because NHEJ is still
higher than HDR with our strategy, which leads to a high percent-
age of cells with null alleles. But, further optimization to establish
timing with which the nuclease mRNA is introduced relative to
re-quiescence would be required before the combined strategy
can be used clinically.
By integratingmultiple scRNA-seq datasets, we used transcrip-
tomics to identify changes in HSPC subpopulations and their cell
cycle status in response to re-quiescence. We found that XRC
(C) Human cell engraftment (human CD45/mouse CD45.1) 16 weeks after transplant in the bone marrow, spleen, and peripheral blood of NSG mice. Data from
individual mice and mean ± SD shown. n = 4 or 6. NS, not significantly different by unpaired t test.
(D and E) Percentage of indicated lineages (B cells [CD19], myeloid cells [CD33], and T cells [CD3]) within the human cell graft in the bone marrow (D) and
peripheral blood (E) of NSG mice. Data from individual mice and mean ± SD shown. n = 4 or 6.
(F andG) Editing outcomes in CD34+ HSPCs before transplanting into NSGmice (F) and in hCD45+mCD45.1 cells from the bonemarrow of NSGmice 16weeks
after transplant (G) (SC, 3 days in SCmedia; SC SC, 6 days in SCmedia; SC XRC, 3 days in SCmedia and 3 additional days in XRC before transplant). Data from
individual mice and mean ± SD shown. n = 3 or 5 for each condition (mice with engraftment < 2%were excluded from this analysis due to insufficient cell number
for amplicon sequencing). *p < 0.05, **p < 0.01 by unpaired t test.
Representative data from experiments performed with two different mPB donors and n = 4–6 biological replicates per donor.




treatment after Cas9 editing results in most cells with transcrip-
tional profiles of quiescent HSCs, similar to CD34+CD38low
HSPCs immediately after thawing. Although mouse HSPCs
have been extensively studied using scRNA-seq, there are rela-
tively few studies analyzing human HSPCs (Buenrostro et al.,
2018; Kowalczyk et al., 2015; Månsson et al., 2007; Moignard
et al., 2013; Pellin et al., 2019; Povinelli et al., 2018; Velten et al.,
2017; Wilson et al., 2015). Combining single-cell transcriptomics
with single-cell genotyping would be a great next step to further
uncover the relationship between gene editing and cell identity
in human HSPCs under XRC treatment and beyond.
Directly addressing the tension between quiescence and HDR
is critical to fully achieve the potential of genome editing. Multiple
types of primary cells potentially suffer from poor HDR that may
be linked to quiescence (Bressan et al., 2017; Schwank et al.,
2013; Urnov et al., 2010; Zhu et al., 2017). Notably, genome edit-
ing of primary human T cells requires activation via anti-CD3/
anti-CD28 stimulation to achieve efficient editing. The re-quies-
cence strategy we develop here could be applicable beyond
HSCs, although one barrier is the paucity of culture models for
various types of primary and stem cells. The potential toxicities
of mTOR and GSK inhibitors will also need to be thoroughly
tested before they are considered for therapeutic purposes.
However, our data indicate that culture conditions and a target
cell’s underlying biology can be just as important as editing mo-
dality to achieve desired genomic outcomes.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Percp-Cy5.5 Mouse Anti-Human CD34 (Clone 561) Biolegend 343612; RRID: AB_2566788
PE-Cy7 Mouse Anti-Human CD38 (Clone HB7) BD Biosciences 335790; RRID: AB_399969
PE Mouse Anti-Human CD90 (Clone 5E10) BD Biosciences 555596; RRID: AB_395970
FITC Mouse Anti-Human CD45RA (Clone HI100) BD Biosciences 555488; RRID: AB_395879
BV421 Rat Anti-Human CD49f (Clone GoH3) BD Biosciences 562598; RRID: AB_2737673
Pacific Blue anti-Human CD45 (Clone HI30) Biolegend 304029; RRID: AB_2174123
FITC anti-mouse CD45.1 Antibody (Clone A20) Biolegend 110706; RRID: AB_313495
APC anti-mouse TER-119/Erythroid Cells Antibody (Ly-76) Biolegend 116212; RRID: AB_313713
PE Mouse Anti-Human CD19 (HIB19) BD Biosciences 555413; RRID: AB_395813
APC Mouse Anti-Human CD33 (WM53) BD Biosciences 551378; RRID: AB_398502
Chemicals, Peptides, and Recombinant Proteins
Rapamycin EMD Millipore 553210
CHIR99021 EMD Millipore 361559
Retinoic Acid (ATRA) Sigma R2625
StemSpan CC110 StemCell Technologies, Inc. 2697
Cas9-NLS UC Berkeley NA
Hoechst33342 ThermoFisher H3570
Pyronin Y Biotang BTBB602
Primestar GXL DNA Polymerase Takara Biosciences R050A
Fixable viability stain 660 BD Biosciences 564405
Critical Commercial Assays
FITC mouse anti-Ki67 kit BD Biosciences 556026
FITC Annexin V Apoptosis Detection Kit with PI Biolegend 640914
P3 primary cell 96-well nucleofector kit Lonza V4SP-3096
Illumina MiSeq reagent kit v2 (300-cycles) Illumina MS-102-2002
Illumina HiSeq 3000/4000 SBS kit (300 cycles) Illumina FC-410-1003
10X Single-cell 30 library gel bead kit v2 10Xgenomics PN-120267
Deposited Data
Amplicon sequencing and single-cell
RNA-sequencing datasets
This paper BioProject ID PRJNA498122
Experimental Models
Mobilized peripheral blood CD34+ Stem/
Progenitor cells
AllCells mPB015F
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse Charles River 005557
Oligonucleotides
Synthetic sgRNA targeting the HBB locus Trilink NA
FP1: cacttagacctcaccctgtg IDT NA
FP2: tatgggacgcttgatgttttct IDT NA
RP1: tatgggacgcttgatgttttct IDT NA
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Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact, Jacob Corn (jacob.corn@
biol.ethz.ch).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
The datasets generated during this study are available at BioProject ID PRJNA498122.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cryopreservedwild-type humanmobilized peripheral bloodCD34+HSPCs frommultiple volunteer donors includingmale and female
whose age ranged from 20-35 were purchased from Allcells, Inc.
METHOD DETAILS
Primary Cell Culture
CD34+ HSPCs were cultured in SC (SFEMII + CC110 (StemCell Technologies)) media, XRC (X-VIVO15 (Lonza) + 5nM Rapamycin
(EMD Millipore) + 3uM CHIR99021 (EMD Millipore)), or SC + 5uM All-trans retinoic acid (Sigma) media unless otherwise noted.
Electroporation for editing experiments
Cas9 RNP synthesis was carried out as previously described (DeWitt et al., 2016). Briefly, 75pmol of Cas9-NLS (UC Berkeley, Ber-
keley, CA) was mixed slowly into Cas9 buffer (20mM HEPES (pH 7.5), 150mM KCl, 1mMMgCl2, 10% glycerol and 1mM TCEP) con-
taining 75pmol of synthetic sgRNA targeting the HBB locus (Synthego). The resulting 7.5ul mixture was incubated for 15minutes to
allow RNP formation. 2x105 CD34+ HSPCs were harvested, washed once with PBS, and resuspended in 20ul of P3 nucleofection
buffer (Lonza, Basel, Switzerland). 7.5ul of RNP mixture and 20ul of cell suspension were combined and added into a Lonza 4d strip
nucleocuvette and were electroporated with program ER-100. 200ul pre-warmedmedia was added to each nucleocuvette and elec-
troporated cells were transferred to culture dishes. Editing outcomes were measured 1-5 days post-electroporation by Next Gener-
ation Amplicon Sequencing.
PCR and Next-Generation Amplicon Sequencing preparation
50-100ng of genomic DNA from edited CD34+ cells was amplified at HBB sites using primer set 1 (Figure S1A). The PCR products
were SPRI cleaned, followed by amplification of 20-50ng of the first PCR product in a second 12 cycle PCR using primer set 2
(Figure S1A). Then the second PCR products were SPRI cleaned, followed by amplification of 20-50ng of the second PCR product
in a third 9 cycle PCR using illlumina compatible primers (primers designed and purchased through the Vincent J. Coates Geno-
mics Sequencing Laboratory (GSL) at University of California, Berkeley), generating indexed amplicons of an appropriate length for
NGS. Libraries from 100-500 pools of edited cells were pooled and submitted to the GSL for paired-end 300 cycle processing
using a version 3 Illumina MiSeq sequencing kit (Illumina Inc., San Diego, CA) after quantitative PCR measurement to determine
molarity.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Software and Algorithms
CRISPResso Pinello et al., 2016 https://github.com/lucapinello/CRISPResso
Seurat v3.1.4 Butler et al., 2018;
Stuart et al., 2019
https://satijalab.org/seurat/
Monocle3 v0.2.1 Trapnell et al., 2014 http://cole-trapnell-lab.github.
io/monocle-release/monocle3/
R v3.6.3 R Development Core Team https://www.r-project.org/
Other
SFEMII StemCell Technologies, Inc. 09655
X-VIVO15 Fisher BW04744Q




Next-Generation Amplicon Sequencing analysis
Samples were deep sequenced on an Illumina MiSeq at 300bp paired-end reads to a depth of at least 10,000 reads. A modified
version of CRISPResso (Pinello et al., 2016) was used to analyze editing outcomes. Briefly, reads were adaptor trimmed then joined
before performing a global alignment between reads and the reference and donor sequences using NEEDLE (Li et al., 2015). Rates of
HDR are calculated as total reads that successfully convert themain (non-PAMout) edit site and have no insertions or deletions within
three basepairs to each side of the cutsite divided by the total number of reads. NHEJ rates are calculated as any reads where an




Human CD34+ cells with or without editing were were first stained with fixable viability stain 660 (1:1000, BD) for 5 min in 37C and
then were stained with Percp-Cy5.5-anti-CD34 (1:50), PE-Cy7-anti-CD38 (1:50), PE-anti-CD90 (1:30), FITC-anti-CD45RA (1:25), and
BV421-anti-CD49f (1:30) (all of the antibodies are fromBD) for 30min in 4C. Samples were then sorted on Aria Fusion Cell Sorter (BD)
or analyzed on LSR Fortessa cytometer (BD).
Cell cycle analysis assays
For Ki67-Hoechst assays, CD34+ cells with or without editing were first stained with fixable viability stain 660 (1:1000, BD) for 5min in
37C and were fixed with Cytofix/Cytoperm buffer (BD) for 15 min in 4C. Cells were stained with FITC-anti-KI67 (1:25, BD, 556027)
for 2hours-overnight in Permwash buffer (BD), then with Hoechst 33342 (1:5000; Life Technologies) for 5 min at RT. Samples were
sorted on a Aria Fusion Cell Sorter (BD) or analyzed on a LSR Fortessa cytometer (BD). For assessment of immunophenotypic
markers together with cell cycle analysis, human CD34+ cells with or without editing were stained with Percp-Cy5.5-anti-CD34
(1:50) and PE-Cy7-anti-CD38 (1:50) for 30 min in 4C before they were stained with fixable viability stain and fixed. For assessment
of cell cycle status without fixation (live cell cycle status), cells with or without editing were stained with Hoechst 33342 (1:1000, In-
vitrogen) for 45min in 37C, and then were stained with Pyronin Y (1:20,000, Invitrogen) for additional 15 min in 37C or were just
stained with Pyronin Y for 15 min in 37C. Samples were then sorted on Aria Fusion Cell Sorter (BD) or analyzed on LSR Fortessa
cytometer (BD).
Apoptosis analysis assays (Annexin V, PI)
Human CD34+ cells with or without editing were first stained with Percp-Cy5.5-anti-CD34 (1:50) and PE-Cy7-anti-CD38 (1:50) for
30min in 4C before they were washed twice with BioLegend’s Cell Staining Buffer (Biolegend) and stained with FITC Annexin V (Bio-
legend, 1:20) and PI (Biolegend, 1:10) for 15minutes at room temperature. Then 400ul of Annexin V binding buffer was added and the
samples were analyzed by LSR Fortessa cytometer (BD).
Single-cell RNA-sequencing
CD34+ CD38low cells were sorted on Aria Fusion Cell Sorter (BD) and single-cell RNA libraries were prepped using Chromium
single cell 30 reagent kit (10x Genomics) according to protocol, starting with 10,000 CD34+ CD38low cells. Prepped libraries
were sequenced on an Illumina Hiseq. 10x sequencing data were processed with Cell Ranger v3.0.2 using default parameters
and GRCh38 as reference. The three datasets (Day1, SC SC and SC XRC) were further processed using Seurat v3.1.4. Cells
with > 200 detected genes and with < 6% of total expression attributed to mitochondrial genes were used for further analysis.
Cell cycle phases were scored using Seurat and the difference (S-G2M), together with the percent of mitochondrial expression
were used to scale datasets. Cells from Day1 and SC SC were merged using integration anchors, clusters identified (dims =
30, resolution = 0.3) and cluster labels transferred to SC XRC. Cluster identities were assigned using 1) markers employed in other
scRNA-seq papers (Buenrostro et al., 2018; Corces et al., 2016; Velten et al., 2017) and 2) markers established in published
bulk FACS-sorted RNA-seq data (Table S1). We minimized bias by assigning the cluster identities to Day1 and SC SC datasets
first before transferring those identities to the experimental SC XRC dataset. Monocle 3 v0.2.1 with default options and Seurat
UMAPs were used to calculate pseudotime. Two partitions were identified for each dataset (Day1+SC SC and SC XRC) with
the HSC/MPP and CMP clusters locating on different partitions. The trajectory end points in the HSC/MPP and CMP clusters
were chosen as root in each partition and the pseudotime of a manually chosen closest cell between both partitions was added
to the second partition.
Xenotransplantation and analysis
8- to 12-week-old NOD-SCID-Il2rg/ (NSG) mice were purchased by Charles River. At day 3 or 6 of culture, 13 106 gene-targeted
mobilized peripheral blood-derived CD34+ cells were injected via tail-vein after sub-lethal irradiation (180cGy, X-ray irradiation with
RS-2000 irradiator, Rad Source). Bone marrow was harvested 16 weeks after transplant for next-generation amplicon sequencing
(NGS genotyping) and multilineage differentiation analysis of human CD45+ cells. For genotyping, bone marrow cells were stained
with Pacific Blue-anti-human CD45 (1:50), FITC-anti-mouse CD45.1(1:100), APC-anti-mouse Ter119 (1:100) for 30 min in 4C and
were sorted on Aria Fusion Cell Sorter (BD). For multilineage differentiation analysis of human CD45+ cells, bone marrow cells
were stained with APC-anti-human CD45 (1:50), AmCyan-anti-mouse CD45.1(1:100), PE-anti-human CD33 (1:100), FITC-anti-hu-
man CD19 (1:100), APC-Cy7-anti-human CD3 (1:100) for 30 min in 4C and were analyzed on LSRFortessa (BD).




QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed with GraphPad Prism (version 7.00 for Mac, GraphPad Software) using unpaired two-tailed t test
analysis. Representative data from nR 2 independent experiments are shown in the figures unless otherwise stated. Each exper-
iment included nR 2 biological replicates unless otherwise noted. More detailed information of experimental replicates is given in
the figure legends of the corresponding experiments.
All values are given in the text as mean (±SD) and a p value < 0.05 was accepted as significant in all analyses, unless otherwise
stated.
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